Should Quality Investors Include NYSE:NVO in Their Portfolio?

In this article we will dive into NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) as a possible candidate for quality investing. Investors should always do their own research, but we noticed NOVO-NORDISK A/S-SPONS ADR showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

Key Considerations for Quality Investors.

• NOVO-NORDISK A/S-SPONS ADR has achieved substantial revenue growth over the past 5 years, with a 15.74% increase. This signifies the company's ability to successfully capture market opportunities and generate sustained revenue growth.
• NOVO-NORDISK A/S-SPONS ADR demonstrates impressive performance in terms of ROIC excluding cash and goodwill, with a 136.0% ratio. This highlights the company's efficient utilization of capital and its focus on maximizing returns for investors.
• NOVO-NORDISK A/S-SPONS ADR maintains a healthy Debt/Free Cash Flow Ratio of 0.54, indicating a strong financial position and prudent debt management. This ratio suggests the company has sufficient free cash flow to cover its debt obligations and highlights its ability to generate cash from operations.
• The Profit Quality (5-year) of NOVO-NORDISK A/S-SPONS ADR stands at 92.21%, highlighting its ability to consistently generate reliable profits. This metric underscores the company's strong business fundamentals and reinforces its position as a financially stable entity.
• NOVO-NORDISK A/S-SPONS ADR has consistently achieved strong EBIT growth over the past 5 years, with a 17.25% increase. This underscores the company's effective management of its operating income and suggests a positive outlook for future profitability.
• With EBIT 5-year growth outpacing its Revenue 5-year growth, NOVO-NORDISK A/S-SPONS ADR showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

Fundamental Analysis Observations

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to NVO. NVO was compared to 197 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making NVO a very profitable company, without any liquidiy or solvency issues. NVO is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes NVO very considerable for growth and quality investing!

Check the latest full fundamental report of NVO for a complete fundamental analysis.

More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.